IRadimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices, and related accessories and services in the United States and internationally. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. The company also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its MRI compatible products through direct sales force and independent distributors. IRadimed Corporation was incorporated in 1992 and is headquartered in Winter Springs, Florida.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Phone407-677-8022
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$30.44 million
Profitability
Miscellaneous
EmployeesN/A
Next Earnings Date4/29/2019 (Estimated)
OptionableNot Optionable
Iradimed (NASDAQ:IRMD) Frequently Asked Questions
What is Iradimed's stock symbol?
Iradimed trades on the NASDAQ under the ticker symbol "IRMD."
How will Iradimed's stock buyback program work?
Iradimed declared that its Board of Directors has authorized a share repurchase program on Sunday, June 4th 2017, which allows the company to buyback $8,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Stock buyback programs are typically a sign that the company's leadership believes its shares are undervalued.
How were Iradimed's earnings last quarter?
Iradimed Corp (NASDAQ:IRMD) released its quarterly earnings data on Wednesday, February, 6th. The medical equipment provider reported $0.14 EPS for the quarter, beating analysts' consensus estimates of $0.13 by $0.01. The medical equipment provider earned $8.34 million during the quarter, compared to the consensus estimate of $8.19 million. Iradimed had a return on equity of 13.78% and a net margin of 20.71%. View Iradimed's Earnings History.
When is Iradimed's next earnings date?
What guidance has Iradimed issued on next quarter's earnings?
Iradimed issued an update on its first quarter 2019 earnings guidance on Wednesday, February, 6th. The company provided earnings per share guidance of $0.12-0.13 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.15. The company issued revenue guidance of $8.3-8.5 million, compared to the consensus revenue estimate of $9.1 million.Iradimed also updated its guidance to EPS.
What price target have analysts set for IRMD?
1 analysts have issued 12-month target prices for Iradimed's stock. Their predictions range from $35.00 to $35.00. On average, they expect Iradimed's share price to reach $35.00 in the next twelve months. This suggests a possible upside of 25.0% from the stock's current price. View Analyst Price Targets for Iradimed.
What is the consensus analysts' recommendation for Iradimed?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Iradimed.
Has Iradimed been receiving favorable news coverage?
News articles about IRMD stock have been trending somewhat negative this week, according to InfoTrie. InfoTrie scores the sentiment of media coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Iradimed earned a media sentiment score of -1.8 on InfoTrie's scale. They also assigned news articles about the medical equipment provider a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the near term.
Who are some of Iradimed's key competitors?
Some companies that are related to Iradimed include K2M Group (KTWO), AtriCure (ATRC), Orthofix Medical (OFIX), Luminex (LMNX), Tactile Systems Technology (TCMD), Cryolife (CRY), Intersect ENT (XENT), Cerus (CERS), AngioDynamics (ANGO), OraSure Technologies (OSUR), Orthopediatrics (KIDS), Axonics Modulation Technologies (AXNX), LeMaitre Vascular (LMAT), SurModics (SRDX) and Antares Pharma (ATRS).
What other stocks do shareholders of Iradimed own?
Who are Iradimed's key executives?
Iradimed's management team includes the folowing people:
- Mr. Roger E. Susi, Founder, Chairman, CEO & Pres (Age 66)
- Mr. Christopher K. Scott, CFO & Sec. (Age 49)
- Mr. John McCreery, Chief Operating Officer (Age 64)
- Mr. Brent Johnson, Exec. VP of Worldwide Sales & Marketing (Age 60)
- Mr. Louis Waldman, Controller (Age 64)
Who are Iradimed's major shareholders?
Iradimed's stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.94%), Ranger Investment Management L.P. (1.74%), Mondrian Investment Partners LTD (1.13%), Navellier & Associates Inc (1.07%), Northern Trust Corp (0.65%) and Cavalier Investments LLC (0.44%). Company insiders that own Iradimed stock include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen, Roger E Susi and Steven M Nardi. View Institutional Ownership Trends for Iradimed.
Which institutional investors are selling Iradimed stock?
IRMD stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., Caxton Associates LP, Algert Global LLC, Macquarie Group Ltd., Timpani Capital Management LLC, O Shaughnessy Asset Management LLC, Advisor Group Inc. and Northern Trust Corp. Company insiders that have sold Iradimed company stock in the last year include Brent Johnson, Christopher K Scott, Francis X Casey, John K Mccreery, Louis S Waldman, Monty K Allen and Steven M Nardi. View Insider Buying and Selling for Iradimed.
Which institutional investors are buying Iradimed stock?
IRMD stock was acquired by a variety of institutional investors in the last quarter, including Navellier & Associates Inc, Acadian Asset Management LLC, Ranger Investment Management L.P., Cavalier Investments LLC, Dupont Capital Management Corp, Mondrian Investment Partners LTD, Bank of America Corp DE and Nkcfo LLC. View Insider Buying and Selling for Iradimed.
How do I buy shares of Iradimed?
Shares of IRMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Iradimed's stock price today?
One share of IRMD stock can currently be purchased for approximately $28.00.
How big of a company is Iradimed?
Iradimed has a market capitalization of $308 million and generates $30.44 million in revenue each year. The medical equipment provider earns $6.30 million in net income (profit) each year or $0.43 on an earnings per share basis.
What is Iradimed's official website?
How can I contact Iradimed?
Iradimed's mailing address is 1025 Willa Springs Dr., Winter Springs FL, 32708. The medical equipment provider can be reached via phone at 407-677-8022 or via email at [email protected]
MarketBeat Community Rating for Iradimed (NASDAQ IRMD)
MarketBeat's community ratings are surveys of what our community members think about Iradimed and other stocks. Vote "Outperform" if you believe IRMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IRMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
